Cantor Fitzgerald Starts Cepheid (CPHD) at Hold; Strongly Positioned, But...

Cantor Fitzgerald initiates coverage on Cepheid (NASDAQ: CPHD) with a Hold. PT $40.00.

Analyst, Sung Ji Nam, siad, "While we believe Cepheid is one of the best positioned companies in the 'in vitro' diagnostic market, leveraged to the fastest growing segments, and with a differentiated technology platform as well as a competitive menu of diagnostic tests, we think Cepheid's longer-term, industry-leading growth potential is fairly reflected at current valuation (~6x 2013E EV/sales). We look for better insight into CT/NG adoption (currently available in Europe and under FDA review in the U.S.) and pipeline development (CLIA-waived flu and HPV in Europe near-term, virology and oncology longer-term), and clearer strategy to achieve meaningful margin improvement and sustainable profitability before turning more constructive on shares."

For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.

Shares of Cepheid closed at $38.19 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Starts Shanghai V-Test Semiconductor (688372:CH) at Overweight
• Evercore ISI Resumes ESAB (ESAB) at In Line
• BofA Securities Starts Tower Semiconductor (TSEM) at Buy